Aytu Biopharma (AYTU) Cash & Equivalents (2011 - 2026)

Aytu Biopharma (AYTU) has 16 years of Cash & Equivalents data on file, last reported at $26.7 million in Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $26.7 million, up 47.0% year-over-year; the trailing twelve-month figure through Mar 2026 was $26.7 million (up 47.0% YoY), and the FY2025 annual result was $31.0 million, up 54.71% from the prior year.
• Cash & Equivalents fell to $26.7 million in Q1 2026 per AYTU's latest filing, from $30.0 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $32.6 million in Q3 2025 and troughed at $18.2 million in Q1 2025.
• A 5-year average of $23.0 million and a median of $20.1 million in 2024 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2022 and 2025: Cash & Equivalents slumped 61.2% in 2022, then jumped 62.27% in 2025.
• A 5-year view of Cash & Equivalents shows it stood at $19.5 million in 2022, then advanced by 0.14% to $19.5 million in 2023, then advanced by 4.45% to $20.4 million in 2024, then soared by 47.2% to $30.0 million in 2025, then retreated by 11.02% to $26.7 million in 2026.
• Business Quant data shows AYTU's Cash & Equivalents at $26.7 million in Q1 2026, $30.0 million in Q4 2025, and $32.6 million in Q3 2025.